All In Biotech

Drug Trial Radar · NCT01087801

A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers

A Placebo Controlled, Double-Blind, Parallel, Multicenter Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers

Last checked: Nov 19, 2026Latest source record: Dec 6, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

64

Actual

Start

Oct 2007

Primary completion

Nov 2009

Study completion Dec 2009

Sponsor

Lead sponsor
ChiRhoClin, Inc.Industry
Sponsor type
Industry
First posted
Mar 16, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The following are the study hypothesis: * Secretin administration compared to placebo will result in a statistically significantly greater percentage of collected fluid samples being predominantly of exocrine pancreas origin when samples are duodenal aspirates. * Secretin administration compared to placebo will result in a statistically significantly greater percentage of collected fluid samples meeting the minimum specifications for use in the indicated laboratory test of DNA mutational analysis.

Conditions

  • Pancreatic Disease

Interventions

  • ChiRhoStimDrug

    Human Secretin for Injection

  • PlaceboDrug

    Saline for Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Endoscopic SampleTime frame: First 5 minutes after treatment administration
  2. Volume of Fluid ≥ 3.5mL (Boolean Expression Evaluated as Yes or no).Time frame: First 5 minutes after treatment administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Saint Louis University

    St Louis, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.